In addition, the observed significant overrepresentation of HLA-A*25 and HLA-C*06 when comparing the frequencies of the HLA alleles in HNSCC patients and a healthy control group also warrants future validation in additional well-defined study samples. This evidence concerns the gene HLA-C and head and neck squamous cell carcinoma.